{"id":"dopamine-agent","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Hallucinations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dopamine agents work by either increasing dopamine synthesis, blocking its reuptake, or directly activating dopamine receptors. This enhances dopaminergic signaling, which is critical for motor control, motivation, and reward processing. Such agents are commonly used to treat conditions characterized by dopamine deficiency or dysfunction.","oneSentence":"A dopamine agent enhances dopaminergic neurotransmission by increasing dopamine availability or receptor activation in the central nervous system.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:44:55.725Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Restless legs syndrome"}]},"trialDetails":[{"nctId":"NCT03648905","phase":"","title":"Clinical Laboratory Evaluation of Chronic Autonomic Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2018-09-06","conditions":"Parkinson's Disease, Multiple System Atrophy, Autonomic Failure","enrollment":89},{"nctId":"NCT00004847","phase":"PHASE1","title":"Diagnosis of Pheochromocytoma","status":"RECRUITING","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2000-03-22","conditions":"Pheochromocytoma, Endocrine Disease, Endocrine Diseases","enrollment":3000},{"nctId":"NCT03947216","phase":"PHASE2","title":"Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-10-23","conditions":"Parkinson Disease","enrollment":117},{"nctId":"NCT01432821","phase":"NA","title":"Blinking and Yawning in Epilepsy: The Role of Dopamine","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2011-09","conditions":"Idiopathic Generalized Epilepsy","enrollment":31},{"nctId":"NCT04469959","phase":"PHASE2","title":"Dopaminergic Dysfunction in Late-Life Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-02-15","conditions":"Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant","enrollment":100},{"nctId":"NCT05824767","phase":"PHASE4","title":"Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2023-04-17","conditions":"Septic Shock, Vasodilatory Shock","enrollment":40},{"nctId":"NCT06075771","phase":"PHASE4","title":"Dopaminergic Therapy for Anhedonia - 2","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-11-21","conditions":"Anhedonia, Depression","enrollment":70},{"nctId":"NCT06484075","phase":"PHASE1, PHASE2","title":"Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms","status":"RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2024-11-21","conditions":"Healthy Volunteers, Alcohol Use Disorder (AUD)","enrollment":180},{"nctId":"NCT05043103","phase":"","title":"Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2021-07-06","conditions":"Advanced Parkinson Disease","enrollment":312},{"nctId":"NCT06785298","phase":"PHASE2, PHASE3","title":"Fexofenadine as Adjuvant Therapy in Parkinson Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-12-10","conditions":"Parkinson Disease","enrollment":46},{"nctId":"NCT03190954","phase":"EARLY_PHASE1","title":"Brain Dopaminergic Signaling in Opioid Use Disorders","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2017-08-17","conditions":"Normal Physiology, Opioid Use Disorders","enrollment":153},{"nctId":"NCT06778265","phase":"PHASE1","title":"An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai UniXell Biotechnology Co., Ltd","startDate":"2025-03-01","conditions":"Parkinson Disease, Idiopathic","enrollment":12},{"nctId":"NCT05009992","phase":"PHASE2","title":"Combination Therapy for the Treatment of Diffuse Midline Gliomas","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-10-20","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma","enrollment":360},{"nctId":"NCT05635409","phase":"PHASE1","title":"A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Region Skane","startDate":"2022-11-30","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT06587217","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2024-10-29","conditions":"Parkinsonian Signs in Older Persons","enrollment":5},{"nctId":"NCT07229664","phase":"PHASE2, PHASE3","title":"Vinpocetine in Patients With Parkinsonian Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-10","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT07273526","phase":"NA","title":"Adrenaline V/s Dopamine in Fuid Refractory Septic Shock","status":"RECRUITING","sponsor":"Laiba Qamar","startDate":"2025-06-01","conditions":"Fluid Refractory Septic Shock, Septic Shock","enrollment":90},{"nctId":"NCT07267065","phase":"PHASE1","title":"AAV2-hAADC for Parkinson's Disease (PDCS-01)","status":"NOT_YET_RECRUITING","sponsor":"Krzysztof Bankiewicz","startDate":"2026-02-01","conditions":"Parkinson's Disease (PD), Early Onset Parkinson Disease","enrollment":9},{"nctId":"NCT04228523","phase":"NA","title":"Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED)","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2020-02-24","conditions":"Parkinson Disease","enrollment":24},{"nctId":"NCT07244640","phase":"","title":"Non-Invasive Fundus Retinal Detection Technology for Early Diagnosis of Parkinson's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-11","conditions":"Parkinson's Disease (PD)","enrollment":200},{"nctId":"NCT07238465","phase":"PHASE3","title":"Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-12","conditions":"Down Syndrome, Autonomic Dysfunction","enrollment":200},{"nctId":"NCT07072910","phase":"PHASE2","title":"Cabergoline for Episodic Migraine","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-12","conditions":"Migraine","enrollment":150},{"nctId":"NCT04317807","phase":"PHASE2","title":"R33: Levetiracetam in Early Psychosis","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-27","conditions":"Early Psychosis","enrollment":65},{"nctId":"NCT06179108","phase":"PHASE2","title":"Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"LB Pharmaceuticals Inc.","startDate":"2023-11-29","conditions":"Schizophrenia","enrollment":359},{"nctId":"NCT02260570","phase":"EARLY_PHASE1","title":"Remediation of Impaired Self-Regulation in Patients With Mild TBI","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2015-08-01","conditions":"Mild Traumatic Brain Injury","enrollment":55},{"nctId":"NCT07173738","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2018-06-11","conditions":"Pulmonary Arterial Hypertension","enrollment":44},{"nctId":"NCT06422208","phase":"PHASE1","title":"Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Penelope J. Hallett, Ph.D.","startDate":"2024-08-07","conditions":"Parkinson Disease","enrollment":6},{"nctId":"NCT07001150","phase":"PHASE2","title":"Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-05-10","conditions":"Parkinson Disease","enrollment":50},{"nctId":"NCT06740812","phase":"PHASE4","title":"Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Nausea and Vomiting, Nausea, Vomiting","enrollment":212},{"nctId":"NCT05290285","phase":"NA","title":"Amino Acids in Patients With Anorexia Nervosa: Double-blind Randomized Study Versus Placebo","status":"RECRUITING","sponsor":"Villa Garda Hospital","startDate":"2022-07-01","conditions":"Anorexia Nervosa","enrollment":92},{"nctId":"NCT04373317","phase":"PHASE4","title":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-24","conditions":"Parkinson's Disease Psychosis","enrollment":358},{"nctId":"NCT02169310","phase":"PHASE1","title":"Neural Basis of Decision-Making Deficits in Traumatic Brain Injury","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2014-11-18","conditions":"Traumatic Brain Injury","enrollment":45},{"nctId":"NCT05636852","phase":"PHASE2","title":"Altropane Dose for Imaging Patients With Suspected Parkinson's Disease","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2023-04-24","conditions":"Parkinson Disease, Movement Disorders","enrollment":15},{"nctId":"NCT05347238","phase":"","title":"Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis","status":"RECRUITING","sponsor":"Mount Sinai Hospital, Canada","startDate":"2023-02-06","conditions":"Late-Onset Neonatal Sepsis, Extreme Prematurity, Neonatal Hypotension","enrollment":550},{"nctId":"NCT05457803","phase":"","title":"Real-world Momentary Assessment of Kratom Use Accompanied by Product Assays: A Natural-history Study for Interdisciplinary Characterization of Kratom Use and Pharmacology","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2022-07-20","conditions":"Chronic Pain, Fatigue, Substance Use Disorders","enrollment":396},{"nctId":"NCT06219915","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2024-03-15","conditions":"Parkinsonian Signs in Older Persons","enrollment":13},{"nctId":"NCT06729658","phase":"EARLY_PHASE1","title":"Dopamine and Brain Computer Interface","status":"COMPLETED","sponsor":"Max Planck Institute for Human Cognitive and Brain Sciences","startDate":"2017-10-01","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT06808932","phase":"PHASE1","title":"VK4-116 Phase I Study With Food-Effect","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2025-11-01","conditions":"Opioid Dependence, Opioid Use Disorder (OUD)","enrollment":48},{"nctId":"NCT05838430","phase":"PHASE4","title":"Solriamfetol and CBT-I in Patients With Insomnia Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-07-31","conditions":"Insomnia","enrollment":60},{"nctId":"NCT06369623","phase":"NA","title":"Monetary Incentive Delay Task for Probing Reward-related Neural Processes","status":"RECRUITING","sponsor":"Stony Brook University","startDate":"2024-04-06","conditions":"Adolescent Development","enrollment":300},{"nctId":"NCT06967831","phase":"","title":"Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2020-03-01","conditions":"Leigh Syndrome (Maternally Inherited, MILS), Leigh Syndrome (AR, AD, XR)","enrollment":80},{"nctId":"NCT06269146","phase":"PHASE2","title":"Pramipexole to Enhance Social Connections","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-05-13","conditions":"Anxiety Disorders, Anxiety, Depression","enrollment":108},{"nctId":"NCT05119075","phase":"NA","title":"Psychological Effects of Levodopa in Parkinson's Disease","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-11-10","conditions":"Parkinson Disease","enrollment":23},{"nctId":"NCT04128683","phase":"EARLY_PHASE1","title":"Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-10-20","conditions":"Anorexia Nervosa","enrollment":31},{"nctId":"NCT05182892","phase":"NA","title":"REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson's Disease Via Automated Speech Analysis","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-12-13","conditions":"Parkinson Disease","enrollment":45},{"nctId":"NCT05765110","phase":"NA","title":"SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-01-03","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT03911726","phase":"NA","title":"Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2020-08-01","conditions":"Schizophrenia","enrollment":140},{"nctId":"NCT05641623","phase":"PHASE2","title":"OSU6162 as add-on in SSRI/SNRI-resistant Depression","status":"RECRUITING","sponsor":"Göteborg University","startDate":"2022-04-21","conditions":"Depression, Depressive Disorder, Treatment-Resistant, Depressive Disorder","enrollment":180},{"nctId":"NCT05369533","phase":"PHASE1, PHASE2","title":"Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-08-01","conditions":"Stroke","enrollment":25},{"nctId":"NCT06344026","phase":"PHASE1","title":"Phase 1/2a Study of ANPD001 in Parkinson Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Aspen Neuroscience","startDate":"2024-01-23","conditions":"Parkinson Disease","enrollment":9},{"nctId":"NCT05890768","phase":"PHASE4","title":"Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2023-05-11","conditions":"Psychosis","enrollment":""},{"nctId":"NCT06497660","phase":"PHASE4","title":"Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2024-08-01","conditions":"Breast Cancer, Neoadjuvant Chemotherapy, Perioperative Period","enrollment":496},{"nctId":"NCT05140148","phase":"PHASE2","title":"Promoting Recovery After STroke With Amantadine","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-02-01","conditions":"Stroke, Ischemic, Stroke Hemorrhagic","enrollment":60},{"nctId":"NCT06832358","phase":"NA","title":"Positive Psychological Intervention for Parkinson's Disease Patients","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2022-02-01","conditions":"Parkinson","enrollment":60},{"nctId":"NCT03416530","phase":"PHASE1","title":"ONC201 in Pediatric H3 K27M Gliomas","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2018-01-25","conditions":"Diffuse Intrinsic Pontine Glioma, Glioma, Malignant","enrollment":134},{"nctId":"NCT06482268","phase":"PHASE1","title":"Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-06-01","conditions":"PD - Parkinson's Disease","enrollment":7},{"nctId":"NCT05285683","phase":"PHASE2","title":"The Role of Brain Dopamine in Chronic Pain","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2024-01-31","conditions":"Chronic Pain","enrollment":10},{"nctId":"NCT06754553","phase":"","title":"Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-02","conditions":"Parkinson Disease","enrollment":100},{"nctId":"NCT04038957","phase":"PHASE1","title":"A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-08-07","conditions":"Schizophrenia","enrollment":22},{"nctId":"NCT05184335","phase":"PHASE3","title":"Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia","status":"RECRUITING","sponsor":"Reviva Pharmaceuticals","startDate":"2022-01-24","conditions":"Schizophrenia","enrollment":690},{"nctId":"NCT04723147","phase":"PHASE4","title":"DTA (Dopaminergic Therapy for Anhedonia) Study","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-01-29","conditions":"Depression, Anhedonia","enrollment":19},{"nctId":"NCT02817698","phase":"EARLY_PHASE1","title":"Imaging the Neurochemistry of Drug Addiction With PET","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-11-29","conditions":"Smoking, Cannabis","enrollment":25},{"nctId":"NCT04802733","phase":"PHASE1","title":"Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"BlueRock Therapeutics","startDate":"2021-05-03","conditions":"Advanced Parkinson's Disease","enrollment":12},{"nctId":"NCT06663891","phase":"NA","title":"Chronic Anergic Depression IDentification - Magnetic Resonance Imaging Exploration in the Elderly of Traits Related to Onset","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-02-01","conditions":"Late Life Depression","enrollment":50},{"nctId":"NCT04369573","phase":"PHASE4","title":"Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock","status":"TERMINATED","sponsor":"Niguarda Hospital","startDate":"2020-05-04","conditions":"Cardiogenic Shock","enrollment":100},{"nctId":"NCT05001217","phase":"PHASE2, PHASE3","title":"Chinese Herbal Medicine Treatment as Adjunct Therapy for Parkinson's Disease","status":"COMPLETED","sponsor":"Hong Kong Baptist University","startDate":"2022-01-01","conditions":"Parkinson Disease","enrollment":160},{"nctId":"NCT05243251","phase":"PHASE3","title":"Olanzapine Anorexia Cachexia","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-12-25","conditions":"Anorexia","enrollment":164},{"nctId":"NCT06365515","phase":"NA","title":"Dopamine, Reward Learning and Sex Hormones","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2024-05","conditions":"Hormonal Changes, Menstrual Cycle","enrollment":90},{"nctId":"NCT05353855","phase":"","title":"Neural Correlates of Impulsivity in Idiopathic REM Sleep Behavior Disorder","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-01-01","conditions":"Parkinson Disease","enrollment":96},{"nctId":"NCT06365190","phase":"NA","title":"Effects of a Periodic Repetitive Transcranial Magenetic Stimulation in Parkinson Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Medical University","startDate":"2020-04-06","conditions":"Transcranial Magnetic Stimulation, Parkinson's Disease","enrollment":47},{"nctId":"NCT04325503","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2021-02-08","conditions":"Parkinsonian Signs in Older Persons","enrollment":14},{"nctId":"NCT06331520","phase":"PHASE3","title":"NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05-01","conditions":"Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy","enrollment":627},{"nctId":"NCT05321602","phase":"PHASE1","title":"Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2021-09-08","conditions":"Schizophrenia, Psychotic Disorders, Mood Disorders","enrollment":89},{"nctId":"NCT03738618","phase":"PHASE3","title":"Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2018-10-29","conditions":"Infertility, Female","enrollment":588},{"nctId":"NCT03740737","phase":"PHASE3","title":"Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2018-10-26","conditions":"Infertility","enrollment":579},{"nctId":"NCT06163352","phase":"NA","title":"The Effect of Vasopressor on Pressure Injury Development","status":"COMPLETED","sponsor":"Koç University","startDate":"2023-05-01","conditions":"Vasopressor Adverse Reaction, Pressure Injury, Pressure Ulcer","enrollment":148},{"nctId":"NCT03000569","phase":"PHASE2","title":"A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-11-30","conditions":"Parkinson Disease","enrollment":29},{"nctId":"NCT03665493","phase":"NA","title":"Dopamine Effect on Inhibitory Control","status":"COMPLETED","sponsor":"Giovanni Mirabella","startDate":"2020-09-30","conditions":"Idiopathic Parkinson's Disease","enrollment":90},{"nctId":"NCT02458690","phase":"PHASE2","title":"eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-07","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":216},{"nctId":"NCT04193527","phase":"PHASE3","title":"A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2020-06-28","conditions":"Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA)","enrollment":172},{"nctId":"NCT04553263","phase":"EARLY_PHASE1","title":"Relapse Prevention in Stimulant Use Disorder","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-06-11","conditions":"Stimulant Use, Relapse, Cognitive Function","enrollment":""},{"nctId":"NCT05884671","phase":"NA","title":"Dopamine and Cognition","status":"COMPLETED","sponsor":"Donders Centre for Cognitive Neuroimaging","startDate":"2021-09-23","conditions":"Sulpiride's Effect on Striatal BOLD Signal During Working Memory Gating, Interaction of Sulpiride, Average Reward Rate and Evidence Accumulation, Interaction of Sulpiride, Average Reward Rate and Cognitive Effort","enrollment":47},{"nctId":"NCT05284526","phase":"NA","title":"EEG Recordings and Analysis in Parkinson's Patients: Towards Adaptive Deep Brain Stimulation by Machine Learning","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-05-09","conditions":"Parkinson Disease","enrollment":30},{"nctId":"NCT04826133","phase":"EARLY_PHASE1","title":"Vitamin D and Cocaine Administration","status":"TERMINATED","sponsor":"Yale University","startDate":"2019-03-27","conditions":"Cocaine Use Disorder","enrollment":4},{"nctId":"NCT01770145","phase":"PHASE4","title":"Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)","status":"COMPLETED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2012-12","conditions":"Parkinson's Disease, Motor Symptoms, Akinesia","enrollment":127},{"nctId":"NCT05389813","phase":"PHASE2, PHASE3","title":"Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia","status":"UNKNOWN","sponsor":"An-Najah National University","startDate":"2021-08-15","conditions":"Anesthesia","enrollment":150},{"nctId":"NCT05713721","phase":"","title":"Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes","status":"UNKNOWN","sponsor":"University Hospital Schleswig-Holstein","startDate":"2023-01-01","conditions":"Parkinson, Dystonia, DYT3","enrollment":120},{"nctId":"NCT03761030","phase":"PHASE4","title":"L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2019-01-09","conditions":"Major Depressive Disorder, Dysthymia, Depression","enrollment":51},{"nctId":"NCT04493320","phase":"PHASE4","title":"1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-02-10","conditions":"Depression, Cognitive Impairment, Gait Impairment","enrollment":5},{"nctId":"NCT03250117","phase":"PHASE1, PHASE2","title":"Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole","status":"TERMINATED","sponsor":"Titan Pharmaceuticals","startDate":"2017-10-10","conditions":"Parkinson Disease","enrollment":6},{"nctId":"NCT04922593","phase":"PHASE1","title":"Relative Bioavailability of LY03010 Compared to Listed Drug","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2021-01-13","conditions":"Schizophrenia, Psychotic Disorders, Mood Disorders","enrollment":281},{"nctId":"NCT02579473","phase":"PHASE1","title":"A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214","status":"UNKNOWN","sponsor":"Serina Therapeutics","startDate":"2016-01","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT05702333","phase":"","title":"Vasoactive-inotropic Support and Levosimendan Use After Lung Transplantation","status":"COMPLETED","sponsor":"Policlinico Hospital","startDate":"2017-02-01","conditions":"Lung Transplant; Complications","enrollment":150},{"nctId":"NCT04566783","phase":"","title":"Identification of Etiopathological and Clinical Factors in Persistent Genital Arousal Disorder","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2020-06-01","conditions":"Restless Genital Syndrome, Sexual Arousal Disorder, Orgasmic Disorder","enrollment":52},{"nctId":"NCT04182399","phase":"NA","title":"Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-04-01","conditions":"Parkinson Disease","enrollment":69},{"nctId":"NCT04650217","phase":"PHASE4","title":"Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-10-07","conditions":"Depressive Disorder","enrollment":1},{"nctId":"NCT04178993","phase":"PHASE1","title":"Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]","status":"COMPLETED","sponsor":"Craig Rush","startDate":"2019-09-01","conditions":"Methamphetamine Use Disorder","enrollment":8},{"nctId":"NCT05670028","phase":"PHASE2","title":"Cerebral Autoregulation Guiding Blood Pressure Management After Revascularization","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-06-04","conditions":"Ischemic Stroke, Revascularization, Blood Pressure","enrollment":100},{"nctId":"NCT05351086","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults","status":"COMPLETED","sponsor":"Pulmatrix Inc.","startDate":"2022-06-09","conditions":"Healthy","enrollment":26},{"nctId":"NCT05658692","phase":"PHASE4","title":"Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dopaminergic drugs"],"phase":"marketed","status":"active","brandName":"Dopamine Agent","genericName":"Dopamine Agent","companyName":"I.R.C.C.S. Fondazione Santa Lucia","companyId":"i-r-c-c-s-fondazione-santa-lucia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A dopamine agent enhances dopaminergic neurotransmission by increasing dopamine availability or receptor activation in the central nervous system. Used for Parkinson's disease, Restless legs syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}